Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 9Biliary Tract Neoplasms 5Stomach Neoplasms 4Cholangiocarcinoma 4Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Advanced Colorectal Cancer 2Thyroid Carcinoma, Anaplastic 1Sarcoma 1Pancreatic cancer, adult 1Pancreatic Cancer Metastatic 1Neuroendocrine Tumors 1Locally Advanced Pancreatic Cancer 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1Appendiceal Neoplasms 1Advanced Pancreatic Cancer 1Advanced Biliary Tract Cancer 1

Interventions

trametinib 2dabrafenib 2Trastuzumab 2zimberelimab 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tislelizumab 1tipifarnib 1surufatinib 1sargramostim 1mercaptoundecahydrododecaborate 1cobimetinib 1aldesleukin 1Vemurafenib 1Tamoxifen 1Radiotherapy 1PLX8394 1Interleukin-12 Subunit p35 1Interleukin-12 1Doxorubicin 1Cisplatin 14-boronophenylalanine-fructose 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × surufatinib × Gastrointestinal × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡